Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

BCG Vaccination Scar Formation in Children Under Five Years :Factors Affecting Its Formation and Subsequent Adverse Effects . (bcgscars)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03548233
Recruitment Status : Not yet recruiting
First Posted : June 7, 2018
Last Update Posted : August 26, 2019
Sponsor:
Information provided by (Responsible Party):
Shimaa Abd elhamid Mahran, Assiut University

Brief Summary:
Study of BCG Vaccination scars of under five years old children . Estimation of the frequency of children without BCG scar after BCG vaccine . Evaluation of factors which may affect scar formation . Tuberculin skin test response in children without BCG scar . Frequency of vaccine adverse effects as injection-site abscess, lymphadenitis, severe local reaction, and disseminated BCG infection.

Condition or disease Intervention/treatment Phase
BCG Vaccination Reaction Biological: bcg vaccine Not Applicable

  Hide Detailed Description

Detailed Description:

Tuberculosis (TB) is an ancient disease, with evidence of skeletal TB found in mummies in both the Old and New World. The causative agent is Mycobacterium tuberculosis, a fastidious, aerobic, acid-fast bacillus Tuberculosis (TB) remains a major global health problem. It ranks as the second leading cause of death from an infectious disease worldwide, after the human immunodeficiency virus (HIV). The latest estimates by the World Health Organization (WHO) reported that there were 9 million new cases in 2011 and 1.4 million TB deaths . Moreover, it is one of the top 10 causes of global mortality and affects low-income countries in particular. About half a million children (0-14 years old) are ill with TB, and 64,000 children died from the disease in 2011 . In Egypt, TB is considered the third most important public health problem after schistosomiasis and hepatitis C .

TB in children is often missed or overlooked due to non-specific symptoms and difficulties in diagnosis. This has made it difficult to assess the actual magnitude of the childhood TB epidemic, which may be higher than currently estimated.

There is an urgent need for public attention, prioritisation, commitment and funding for this disease that today should never take the life of a child.

Bacillus Calmette-Guérin (BCG) vaccine : a live attenuated vaccine that has been in use since 1921, is the most widely used vaccine worldwide . BCG is efficacious against the most severe forms of tuberculosis (TB) such as tuberculosis meningitis (73% protection) and miliary TB (77% protection) in children younger than 5 years .

It is one of the mandatory vaccines recommended by the ministry of health(MOH) of Egypt.

BCG vaccination became compulsory in all governorates of Egypt since 1974 . the recommended schedule of BCG is eight weeks postnatal. The usual response to administer BCG vaccine is the development of erythema or a papule at around 2 weeks, followed by an ulcer and healing with a scar at 6 weeks at the site of the injection.

Although the size of reaction after vaccination is not generally thought to influence the degree of protection offered by BCG, the presence of the BCG scar has been used as a criterion to assess the uptake of vaccination .

However, the sensitivity of BCG scar as an index of vaccination status is still the subject of controversy. Failure to form scar may be related to factors such as lack of maturation of the immune system, faulty technique or unipotent vaccine.

Adverse effects of Bcg vaccine: were classified, according to World Health Organization definitions , as injection-site abscess, lymphadenitis, severe local reaction, and disseminated BCG infection.

Tuberculin skin test response:

The reaction is read by measuring the diameter of induration (palpable raised, hardened area) across the forearm (perpendicular to the long axis) in millimeters. If there is no induration, the result should be recorded as "0 mm". Erythema (redness) should not be measured.

  • 5 mm or more is positive in
  • An HIV-positive person
  • Persons with recent contacts with a TB patient
  • Persons with nodular or fibrotic changes on chest X-ray consistent with old healed TB
  • Patients with organ transplants, and other immunosuppressed patients
  • 10 mm or more is positive in
  • Recent arrivals (less than five years) from high-prevalence countries
  • Injection drug users
  • Residents and employees of high-risk congregate settings (e.g., prisons, nursing homes, hospitals, homeless shelters, etc.)
  • Mycobacteriology lab personnel
  • Persons with clinical conditions that place them at high risk (e.g., diabetes, prolonged corticosteroid therapy, leukemia, end-stage renal disease, chronic malabsorption syndromes, low body weight, etc.)
  • Children less than four years of age, or children and adolescents exposed to adults in high-risk categories
  • 15 mm or more is positive in
  • Persons with no known risk factors for TB.

the study aims to• Estimate the frequency of children without BCG scar after bcg vaccination.

  • Evaluate factors which may affect scar formation.
  • Tuberculin skin test response in children without BCG scars if indicated.
  • Frequency of vaccine adverse effects

Exclusion criteria:

  • Infants with skin lesion on the left forearm.
  • Infant treated with steroids or intravenous immune globulins.
  • Infants with immunodeficiency.
  • Severe sepsis.
  • Infants with congenital anomalies.

All cases included in the study will be subjected to

  • Full clinical history including: Birth weight, nutritional status, gender, gestational age, weight at time of vaccination, mother awareness.
  • Detailed clinical examination: including site of bcg scar.
  • Tuberculin test in negative BCG scar children.
  • Revaccination of negative BCG scar children.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Intervention Model: Single Group Assignment
Intervention Model Description: bcg vaccine
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: BCG Vaccination Scar Formation in Children Under Five Years :Factors Affecting Its Formation and Subsequent Adverse Effects .
Estimated Study Start Date : December 1, 2019
Estimated Primary Completion Date : December 1, 2020
Estimated Study Completion Date : December 1, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Scars

Arm Intervention/treatment
bcg vaccinated
children under five year vaccinated by bcg vaccine
Biological: bcg vaccine
live attenuated vaccine




Primary Outcome Measures :
  1. number of children without bcg scar after bcg vaccination and factors that may lead to that nummber of children with adverse effects from bcg vaccine using clinical data about children included in the study [ Time Frame: one year ]
    bcg vaccination reaction and adverse effects and factors affecting scar formation



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Months to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

- Children between 6 and 60 months of age.

Exclusion Criteria:

  • • Infants with skin lesion on the left forearm.

    • Infant treated with steroids or intravenous immune globulins.
    • Infants with immunodeficiency and malnutrition.
    • Severe sepsis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03548233


Contacts
Layout table for location contacts
Contact: shimaa mahran, master 01140574639 shimaamahran88@gmail.com

Sponsors and Collaborators
Assiut University
Investigators
Layout table for investigator information
Principal Investigator: mohamed ghazaly, professor assiut universitypediatric hospital
Principal Investigator: mustafa embaby, assistprof assiut universitypediatric hospital

Layout table for additonal information
Responsible Party: Shimaa Abd elhamid Mahran, principal investigator, Assiut University
ClinicalTrials.gov Identifier: NCT03548233     History of Changes
Other Study ID Numbers: bcgvaccinationscars
First Posted: June 7, 2018    Key Record Dates
Last Update Posted: August 26, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Vaccines
BCG Vaccine
Immunologic Factors
Physiological Effects of Drugs
Adjuvants, Immunologic